An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Study Purpose

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Key

Inclusion Criteria:

  • - Resectable cutaneous melanoma metastatic to a lymph node and at high risk of recurrence.
  • - Complete resection within 13 weeks prior to the first dose of pembrolizumab.
  • - Disease free at study entry (after surgery) with no loco-regional relapse or distant metastasis and no clinical evidence of brain metastases.
  • - Has an formalin fixed paraffin embedded (FFPE) tumor sample available suitable for sequencing.
  • - Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
  • - Normal organ and marrow function reported at screening.
Key

Exclusion Criteria:

  • - Prior malignancy, unless no evidence of that disease for at least 5 years prior to study entry.
  • - Prior systemic anti-cancer treatment (except surgery and interferon for thick primary melanomas.
Radiotherapy after lymph node dissection is permitted)
  • - Live vaccine within 30 days prior to the first dose of pembrolizumab.
  • - Transfusion of blood or administration of colony stimulating factors within 2 weeks of the screening blood sample.
  • - Active autoimmune disease.
  • - Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab.
  • - Solid organ or allogeneic bone marrow transplant.
  • - Pneumonitis or a history of (noninfectious) pneumonitis that required steroids.
  • - Prior interstitial lung disease.
  • - Clinically significant heart failure.
  • - Known history of human immunodeficiency virus (HIV) - Known active hepatitis B or C.
- Active infection requiring treatment

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03897881
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

ModernaTX, Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Australia, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Melanoma
Arms & Interventions

Arms

Experimental: mRNA-4157 and Pembrolizumab

Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.

Active Comparator: Pembrolizumab

Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.

Interventions

Drug: - mRNA-4157

Individualized Neoantigen Therapy

Biological: - Pembrolizumab

Intravenous infusion

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of Arizona, Tucson, Arizona

Status

Recruiting

Address

University of Arizona

Tucson, Arizona, 85719

Site Contact

Montaser Shaheen

shaheenm@email.arizona.edu

812-230-1521

San Francisco, California

Status

Recruiting

Address

California Pacific Medical Center Research Institute -CPMCRI

San Francisco, California, 94115

Site Contact

Kevin Kim, MD

kimkb@sutterhealth.org

415-885-8600

Angeles Clinic and Research Institute, Santa Monica, California

Status

Recruiting

Address

Angeles Clinic and Research Institute

Santa Monica, California, 90404

Site Contact

Mark Faries, MD

mfaries@theangelesclinic.org

310-582-7020

University of Colorado Cancer Center, Aurora, Colorado

Status

Recruiting

Address

University of Colorado Cancer Center

Aurora, Colorado, 80045

Site Contact

Karl Lewis, MD

karl.lewis@ucdenver.edu

720-848-0637

New Haven, Connecticut

Status

Recruiting

Address

Smilow Cancer Center at Yale New Haven Hospital

New Haven, Connecticut, 06520

Site Contact

Sarah Weiss, MD

sarah.weiss.sw842@yale.edu

203-785-6378

Lombardi Cancer Center, Washington, District of Columbia

Status

Recruiting

Address

Lombardi Cancer Center

Washington, District of Columbia, 20007

Site Contact

Geoffrey Gibney, MD

geoffrey.t.gibney@gunet.georgetown.edu

813-745-3437

Orlando Health UF Health Cancer Center, Orlando, Florida

Status

Recruiting

Address

Orlando Health UF Health Cancer Center

Orlando, Florida, 32806

Site Contact

Sajeve Thomas

Sajeve.thomas@orlandohealth.com

954-663-7551

UPMC Hillman Cancer Center, Chicago, Illinois

Status

Recruiting

Address

UPMC Hillman Cancer Center

Chicago, Illinois, 60637

Site Contact

Jason Luke

lukejj@upmc.edu

773-702-0963

Massachusetts General Hospital, Boston, Massachusetts

Status

Recruiting

Address

Massachusetts General Hospital

Boston, Massachusetts, 02114

Site Contact

Ryan Sullivan, MD

rsullivan7@mgh.harvard.edu

617-632-5470

Dana Farber Cancer Institute, Boston, Massachusetts

Status

Recruiting

Address

Dana Farber Cancer Institute

Boston, Massachusetts, 02115

Site Contact

Elizabeth Buckbinder

elizabeth_buckbinder@dfci.harvard.edu

617-632-9271

Washington University School of Medicine, Saint Louis, Missouri

Status

Recruiting

Address

Washington University School of Medicine

Saint Louis, Missouri, 63110

Site Contact

Leonel Hernandez Aya, MD

lhernand@dom.wustl.edu

314-747-7510

Hackensack University Medical Center, Hackensack, New Jersey

Status

Recruiting

Address

Hackensack University Medical Center

Hackensack, New Jersey, 07601

Site Contact

Andrew Pecora, MD

andrew.pecora@hackensackmeridian.org

551-996-5814

NYU Langone Medical Center, New York, New York

Status

Recruiting

Address

NYU Langone Medical Center

New York, New York, 10016

Site Contact

Jeffrey Weber, MD

jeffrey.weber@nyumc.org

212-731-6262

Providence Cancer Institute, Portland, Oregon

Status

Recruiting

Address

Providence Cancer Institute

Portland, Oregon, 97213

Site Contact

Mathew Taylor

matthew.taylor@providence.org

503-494-8534

Sarah Cannon Cancer Center, Nashville, Tennessee

Status

Recruiting

Address

Sarah Cannon Cancer Center

Nashville, Tennessee, 37203

Site Contact

Meredith McKean, MD

mmckean@tnonc.com

615-329-7274

Texas Oncology PA, Dallas, Texas

Status

Recruiting

Address

Texas Oncology PA

Dallas, Texas, 75246

Site Contact

Charles Cowey, MD

lance.cowey@usoncology.com

214-370-1000

International Sites

Melanoma Institute Australia, North Sydney, New South Wales, Australia

Status

Active, not recruiting

Address

Melanoma Institute Australia

North Sydney, New South Wales, 2060

Westmead Hospital, Westmead, New South Wales, Australia

Status

Active, not recruiting

Address

Westmead Hospital

Westmead, New South Wales, 2145

Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

Status

Active, not recruiting

Address

Princess Alexandra Hospital

Woolloongabba, Queensland, 4102

Affinity Clinical Research, Murdoch, Western Australia, Australia

Status

Active, not recruiting

Address

Affinity Clinical Research

Murdoch, Western Australia, 6150

St John of God Hospital Subiaco, Subiaco, Western Australia, Australia

Status

Recruiting

Address

St John of God Hospital Subiaco

Subiaco, Western Australia, 6008

Site Contact

Tarek Meniawy

tarek@westernoncology.com.au

+61861023640

Stay Informed & Connected